The available biologics for psoriasis basically target the function of TNF-α, IL-17A orIL-12/23 includes etanercept (anti-TNF receptor fusion protein), adalimumab and infliximab (anti-TNFα antibodies), anti-IL-17(receptor) molecules and ustekinumab [9]. The gene discussed is IL17A; the disease is psoriasis.